TowerView LLC’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

TowerView LLC’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-833	Closed	-$158K	–	32
2022 Q2	$158K	Sell	833 -834	-50%	-$168K	0.08%	27
2022 Q1	$415K	Sell	1,667 -2,833	-63%	-$448K	0.2%	26
2021 Q4	$701K	Hold	4,500	–	–	0.35%	25
2021 Q3	$902K	Hold	4,500	–	–	0.47%	23
2021 Q2	$1.15M	Sell	4,500 -167	-4%	-$41.7K	0.69%	19
2021 Q1	$1.24M	Buy	4,667 +334	+8%	+$105K	0.77%	18
2020 Q4	$1.6M	Buy	4,333 +333	+8%	+$95.5K	1.14%	11
2020 Q3	$977K	Buy	4,000 +1,417	+55%	+$441K	0.75%	12
2020 Q2	$744K	Buy	+2,583	New	+$761K	0.57%	13

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

TowerView LLC's EIGR Position: Q3 2022 in Review

TowerView LLC sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2022, closing a stake of 833 shares — an estimated $158K sold.

TowerView LLC first reported a position in EIGR in Q2 2020 and held it in 9 quarters. The position peaked at $1.6M in Q4 2020. 92 funds tracked by Wall St. Rank hold EIGR as of Q3 2022.

TowerView LLC reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
TowerView LLC sold 833 Eiger BioPharmaceuticals, Inc. shares in Q3 2022, an estimated $158K.
TowerView LLC first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2020 and held it in 9 quarters.
TowerView LLC's Eiger BioPharmaceuticals, Inc. position peaked at $1.6M in Q4 2020.
92 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2022.

Based on TowerView LLC's 13F filing for Q3 2022, filed 3 Nov 2022.